Michael Crowley - Bio Rad President
| BIO Stock | USD 290.86 1.89 0.65% |
President
Mr. Michael Crowley is Executive Vice President Global Commercial Operations of the Company. He was appointed Executive Vice President, Global Commercial Operations in December 2014. Previously he was Vice President, Commercial Manager, Europe from 2012 to 2014 and Commercial Manager, Clinical Diagnostics Group, Europe from 2011 to 2012 and Division Manager of the Clinical Diagnostics Group North American Sales Organization from 2008 to 2011. Prior to that, he was the Clinical Diagnostics U.S. National Sales Manager since joining BioRad in 1998. since 2014.
| Age | 62 |
| Tenure | 10 years |
| Address | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 |
| Phone | 510 724 7000 |
| Web | https://www.bio-rad.com |
Latest Insider Transactions
Michael Crowley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Crowley against Bio Rad stock is an integral part of due diligence when investing in Bio Rad. Michael Crowley insider activity provides valuable insight into whether Bio Rad is net buyers or sellers over its current business cycle. Note, Bio Rad insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bio Rad'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Crowley few days ago Acquisition by Michael Crowley of 520 shares of Bio Rad subject to Rule 16b-3 | ||
Michael Crowley over a week ago Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Michael Crowley over two weeks ago Acquisition by Michael Crowley of 433 shares of Bio Rad subject to Rule 16b-3 |
Bio Rad Management Efficiency
The company has Return on Asset of 0.0177 % which means that on every $100 spent on assets, it made $0.0177 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0694) %, meaning that it generated no profit with money invested by stockholders. Bio Rad's management efficiency ratios could be used to measure how well Bio Rad manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of April 2024, Return On Tangible Assets is likely to grow to -0.05. In addition to that, Return On Capital Employed is likely to drop to 0.03. At this time, Bio Rad's Total Assets are very stable compared to the past year. As of the 18th of April 2024, Non Current Assets Total is likely to grow to about 9.7 B, though Non Currrent Assets Other are likely to grow to (1.4 T).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ryan Weispfenning | Medtronic PLC | N/A | |
| Geoffrey Martha | Medtronic PLC | 54 | |
| Michael Rousseau | Abbott Laboratories | 62 | |
| Robert Hoedt | Medtronic PLC | 64 | |
| Shakil Lakhani | InMode | 41 | |
| Christopher Christoforou | Nevro Corp | 50 | |
| Thomas Frinzi | Abbott Laboratories | 60 | |
| Robert Funck | Abbott Laboratories | 63 | |
| Heather Mason | Abbott Laboratories | 56 | |
| Glenn Boehnlein | Stryker | 62 | |
| JeanYves Pavee | Abbott Laboratories | 51 | |
| Bradley Lerman | Medtronic PLC | 63 | |
| Deepak Nath | Abbott Laboratories | 43 | |
| Benjamin CFA | Monogram Orthopaedics Common | 40 | |
| Johonna Pelletier | CONMED | 51 | |
| Andrew Lane | Abbott Laboratories | 49 | |
| Carol Surface | Medtronic PLC | 54 | |
| Bijoy Sagar | Stryker | 49 | |
| Geoff Martha | Medtronic PLC | N/A | |
| Brent Ladd | Stryker | N/A | |
| David Floyd | Stryker | 56 | |
Management Performance
| Return On Equity | -0.0694 | ||||
| Return On Asset | 0.0177 |
Bio Rad Laboratories Leadership Team
Elected by the shareholders, the Bio Rad's board of directors comprises two types of representatives: Bio Rad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Rad's management team and ensure that shareholders' interests are well served. Bio Rad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Rad's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Stark, Principal Accounting Officer, Vice President Controller | ||
| Ajit Ramalingam, Senior Vice President Chief Accounting Officer | ||
| Shannon Hall, Executive Vice President and Presidentident, Life Science Group | ||
| Jeffrey Edwards, Independent Director | ||
| Lee Boyd, Senior Pacific | ||
| Andrew Last, Chief Operating Officer, Executive Vice President | ||
| Yong Chung, Vice Relations | ||
| Tania DeVilliers, Corporate Director | ||
| Arnold Pinkston, Independent Director | ||
| Christine Tsingos, CFO and Executive VP | ||
| Timothy Ernst, Executive Vice President General Counsel and Secretary | ||
| Ronald Hutton, Vice President Treasurer | ||
| Joel McComb, Director | ||
| Jim Barry, Senior Manufacturing | ||
| Alice Schwartz, Director | ||
| Gregory Hinckley, Lead Independent Director | ||
| Michael Crowley, Executive Vice President - Global Commercial Operations | ||
| Simon May, Executive Vice President and Presidentident - Life Science Group | ||
| Melinda Litherland, Independent Director | ||
| John Hertia, Executive Vice President, President, Clinical Diagnostics Group | ||
| John Goetz, COO and Executive VP | ||
| Louis Drapeau, Independent Director | ||
| Shawn Soderberg, Executive Vice President General Counsel, Secretary | ||
| Annette Tumolo, Executive Vice President and Presidentident, Life Science Group | ||
| Dara Wright, Executive Vice President and President of the Clinical Diagnostics Group | ||
| Norman Schwartz, Chairman of the Board, President, Chief Executive Officer | ||
| Ilan Daskal, Chief Financial Officer, Executive Vice President | ||
| Matthew Werner, Senior Officer | ||
| Colleen Corey, Executive Resources | ||
| Deborah Neff, Independent Director | ||
| Giovanni Magni, Executive Vice President, Chief Strategy Officer | ||
| Robert Malchione, Independent Director |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Rad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0694 | ||||
| Return On Asset | 0.0177 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 8.37 B | ||||
| Shares Outstanding | 23.42 M | ||||
| Shares Owned By Insiders | 15.23 % | ||||
| Shares Owned By Institutions | 81.70 % | ||||
| Number Of Shares Shorted | 564.75 K | ||||
| Price To Earning | 2.90 X |
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving together with Bio Stock
| 0.62 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Bio Stock
| 0.57 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Bio Stock analysis
When running Bio Rad's price analysis, check to measure Bio Rad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Rad is operating at the current time. Most of Bio Rad's value examination focuses on studying past and present price action to predict the probability of Bio Rad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Rad's price. Additionally, you may evaluate how the addition of Bio Rad to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Bio Rad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.56) | Earnings Share (21.81) | Revenue Per Share 91.453 | Quarterly Revenue Growth (0.07) | Return On Assets 0.0177 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.